In the latest video from the ASCO round table, Drs. Nate Pennell, Mary Pinder and Jack West review the results presented at ASCO 2013 from the PRONOUNCE trial of the ECOG 4599 trial regimen compared with carboplatin/Alimta (pemetrexed) followed by maintenance Alimta.

You can watch the video here: http://cancergrace.org/lung/2013/06/14/pronounce-trial/

We welcome your questions and comments here.

JimC
Forum moderator

In the latest ASCO 2013 video, Drs. Mary Pinder, Nate Pennell, and Jack West discuss the results presented at ASCO 2013 of the GALAXY-1 trial of the HSP90 inhibitor ganetespib combined with Taxotere (docetaxel) as second line therapy for advanced NSCLC.

You can view the video here: http://cancergrace.org/lung/2013/06/19/galaxy-1-ganetespib-hsp90/

We welcome your questions and comments here.

JimC
Forum moderator

In a new video, Dr. Mary Pinder reviews promising studies from ASCO 2013 on second generation ALK inhibitors LDK-378, CH5424802, and AP26113 in patients with ALK-positive advanced NSCLC, including impressive activity in crizotinib-refractory patients and those with brain mets.

You can view the video here: http://cancergrace.org/lung/2013/06/24/second-generation-alk-inhibitors/

We welcome your questions and comments here.

JimC
Forum moderator

GRACE videos from ASCO 2013 continue as Dr. Nate Pennell from Cleveland Clinic reviews the LUME Lung-1 trial presented by Reck at ASCO 2013, of Taxotere with or without nindetanib (BIBF-1120), an anti-angiogenic multikinase inhibitor, in advanced NSCLC.

You can view the video here: http://cancergrace.org/lung/2013/06/26/nindetanib-bibf1120-lume-lung-1/

We welcome your questions and comments here.

JimC
Forum moderator

In another ASCO 2013 video roundtable, Drs. Nate Pennell, Mary Pinder, and Jack West discuss trials presented at ASCO 2013 testing the potential value of molecular marker testing to select optimal chemo for advanced non-small cell lung cancer (NSCLC).

You can view the video here: http://cancergrace.org/lung/2013/06/10/madeit-sclg-molecular-selection-…

We welcome your questions and comments here.

JimC
Forum moderator

In the newest ASCO 2013 video, Dr. Mary Pinder of Moffitt Cancer Center reviews the CUSTOM trial, in which the study of molecular markers was expanded to patients with small cell lung cancer and thymic carcinomas.

You can view the video here: http://cancergrace.org/lung/2013/06/28/custom-trial-sclc-thymic-carcino…

We welcome your questions and comments here.

JimC
Forum moderator

In today's ASCO 2013 video, Drs. Mary Pinder, Nate Pennell, and Jack West discuss developments with selumetinib and other MEK inhibitors as a potential target for the 20-25% of NSCLC patients with a KRAS mutation.

You can view the video here: http://cancergrace.org/lung/2013/07/03/mek-inhibitor-update-asco-2013/

We welcome your questions and comments here.

JimC
Forum moderator

More breaking news from ASCO 2013, as Drs. Nate Pennell, Mary Pinder, and Jack West discuss the START trial of L-BLP-25 (tecemotide) immunotherapy in locally advanced NSCLC.

You can view the video here: http://cancergrace.org/lung/2013/07/05/start-trial-asco-2013/

We welcome your questions and comments here.

JimC
Forum moderator

ASCO 2013 videos continue, as Drs. Jack West, Mary Pinder, and Nate Pennell discuss options for managing acquired resistance to EGFR TKIs and ALK inhibitors in patients with advanced NSCLC and a driver mutation.

You can view the video here: http://cancergrace.org/lung/2013/07/08/acquired-resistance-targeted-rx-…

We welcome your questions and comments here.

JimC
Forum moderator

Just ran across this web-page for the first time tonight: http://www.lungcancerprofiles.com/lung_cancer_information.aspx

Don't know much about it, but I clicked around a bit and I like what I saw. Thought I'd share.

xoxo,
Laya